There are 2789 resources available
1205P - Treatment sequencing and duration of subsequent tyrosine kinase inhibitors in ALK+ non-small cell lung cancer patients treated with brigatinib in the US
Presenter: Mohammad Jahanzeb
Session: ePoster Display
1206P - UNcommon EGFR mutations: International Case series on efficacy of Osimertinib in Real-life practice in first-liNe setting (UNICORN)
Presenter: Jair Bar
Session: ePoster Display
1209P - RELAY, ramucirumab plus erlotinib (RAM+ERL) in untreated metastatic EGFR-mutant NSCLC (EGFR+NSCLC): Association between TP53 status and clinical outcome
Presenter: Makoto Nishio
Session: ePoster Display
1256P - Capmatinib safety update in MET dysregulated NSCLC from the GEOMETRY mono-1 trial
Presenter: Rebecca Heist
Session: ePoster Display
1257P - Effect of hepatic impairment on tepotinib pharmacokinetics
Presenter: Thomas Marbury
Session: ePoster Display
1258P - MET exon14 skipping in non-small cell lung cancer: Clinicopathological characteristics, treatments, and efficacy of crizotinib according to functional analysis: AFonMET - GFPC study
Presenter: Hélène Babey
Session: ePoster Display
1259P - Real-world next-generation sequencing (NGS) and treatment (Tx) patterns in non-small cell lung cancer (NSCLC) patients (pts) with MET exon 14 skipping mutations (METex14)
Presenter: Xiuning Le
Session: ePoster Display
1260P - Clinical outcomes of patients with BRAF<sup>v</sup>⁶⁰⁰-mutated metastatic NSCLC (mNSCLC) receiving first-line (1L) dabrafenib-trametinib vs other standard of care in real-world practice
Presenter: Barbara Melosky
Session: ePoster Display
1261P - Trastuzumab/pertuzumab combination therapy in advanced pre-treated HER2-mutated non-small cell lung cancer: Results of a DRUP trial cohort
Presenter: Jade van Berge Henegouwen
Session: ePoster Display